The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trialsMark Haas, Michael Mengel, Brian J. Nankivell et al.|American Journal of Transplantation|2017Cited by 1k
Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trialWilliam H. Marks, Denis Glotz, Nizam Mamode et al.|American Journal of Transplantation|2019Cited by 146
The Banff 2022 Kidney Meeting Work Plan: Data-driven refinement of the Banff Classification for renal allograftsCandice Roufosse, Chris Wiebe, Maarten Naesens et al.|American Journal of Transplantation|2023Cited by 49